+ T helper cells are known to play an integral role in the generation of CD8 + T-cell immune responses. We have previously shown that co-administration of DNA vaccines containing E6 or E7 protein of human papillomavirus 16 (HPV-16) combined with DNA encoding invariant (Ii) chain in which class II-associated Ii peptide (CLIP) region is replaced with the CD4 + T helper epitope, PADRE (Pan-DR-epitope) (Ii-PADRE DNA) enhanced HPV antigen-specific CD8 + T-cell immune responses in vaccinated mice. In the current study, we investigated the enhancement of HPV E7-specific CD8 + T-cell immune responses by PADRE-specific CD4 + T cells. We showed that intradermal administration of Ii-PADRE DNA at the same location as E7-expressing DNA is necessary to generate strong E7-specific CD8 + T-cell immune responses. We also showed that PADRE-specific CD4 + T cells generated by Ii-PADRE DNA vaccination expressed Th1 cytokine profile. Furthermore, our in vitro study demonstrated that PADRE-specific CD4 + T cells stimulated with PADRE-loaded dendritic cells secrete IL-2 that leads to the proliferation of E7-specific CD8 + T cells. Thus, our data suggest that activated PADRE-specific CD4 + T helper cells may be required at the vicinity of E7-specific CD8 + T cells where they secrete IL-2, which enhances the E7-specific CD8 + T-cell immune responses generated by DNA vaccination.
Introduction
DNA vaccines have become an attractive and potentially effective approach for antigen-specific immunotherapy. Naked DNA has numerous advantages including safety, stability, simplicity in production and the ability to generate sustained levels of antigen expression in cells (for a review, see Donnelly et al. 1 and Gurunathan et al.
2
). Furthermore, multiple kinds of DNA vaccines can be repeatedly administered without the concerns associated with viral vectors. In addition, DNA can be efficiently delivered into dendritic cells (DCs) via intradermal administration using a gene gun. These DNA-expressing DCs mature and migrate to the draining lymph nodes, where they prime CD4 + and CD8 + T cells in vivo. 3, 4 However, DNA vaccines suffer from the drawback of low immunogenicity. The potency of DNA vaccines may be enhanced by using strategies to modify the properties of DCs to boost vaccine-elicited immune responses (for review, see Hung and Wu 5 and Tsen et al. . Furthermore, CD4 + T cells can interact with macrophages and NK cells to enhance tumor destruction at tumor sites. 8, 9 Thus, it is desirable to generate antigen-specific CD4 + T cells in addition to antigen-specific CD8 + T cells in vaccination strategies. In our previous study, we successfully generated antigen-specific CD4 + T-cell immune responses in mice by employing a DNA vaccine encoding the invariant (Ii) chain molecule, an essential component of the major histocompatibility complex (MHC) class II-mediated antigen presentation process. 10 In the endoplasmic reticulum, MHC class II molecules assemble and bind with the Ii chain. The class II-associated Ii peptide (CLIP) region of the Ii chain occupies the MHC class II peptidebinding grove. The Ii chain is then degraded until only the CLIP region remains. This region prevents premature binding of the antigenic peptide into the MHC class II peptide-binding groove. CLIP is later replaced in the lysosome by one of the antigenic peptides. We have employed a DNA vaccine encoding the Ii chain in which the CLIP region is replaced with a CD4 + T helper epitope, PADRE (Pan-DR-epitope) (Ii-PADRE DNA). Vaccination of mice with the Ii-PADRE DNA increased the number of PADRE-specific CD4 + T cells in the immunized C57BL/6 mice. In addition, co-administration of Ii-PADRE DNA and DNA vaccines containing either the E6 or E7 protein of human papillomavirus type 16 (HPV-16) led to enhanced HPV antigen-specific CD8 + T-cell immune responses and potent protective and therapeutic antitumor effects against an E6/E7-expressing tumor model, TC-1, in mice. 10 These results indicate that co-administration of DNA vaccines with Ii-PADRE DNA represents an effective approach for enhancing the generation of PADRE-specific CD4 + T cells and eliciting stronger antigen-specific CD8 + T-cell immune responses. In the current study, we aim to gain insights into the enhancement of HPV E7-specific CD8 + T-cell immune responses by PADRE-specific CD4 + T cells in vaccinated mice. We showed that intradermal administration of Ii-PADRE DNA is required to be at the same location as E7-expressing DNA to generate strong E7-specific CD8 + T-cell immune responses. Furthermore, we showed that the PADRE-specific CD4 + T cells generated by vaccination with Ii-PADRE DNA expressed Th1 cytokine profile. Our in vitro study demonstrated that PADRE-specific CD4 + T cells stimulated with PADRE-loaded DCs secrete IL-2 that leads to the proliferation of E7-specific CD8 + T cells.
Results
Intradermal administration of CRT/E7 and Ii-PADRE DNA at the same location generates stronger E7-specific CD8 + T-cell immune responses compared to administration of CRT/E7 and Ii-PADRE DNA separately at different locations
We have previously demonstrated that vaccination with CRT/E7 and Ii-PADRE DNA significantly enhanced the E7-specific CD8 + T-cell immune responses. 10 However, it was not clear whether the Ii-PADRE DNA needed to be administered in the same location as CRT/E7 DNA to achieve the observed enhancement in E7-specific CD8 + T cells. To address this issue, we vaccinated C57BL/6 mice intradermally via gene gun with the DNA vaccine encoding CRT/E7 with Ii-PADRE either administered together at the same location (CRT/E7+Ii-PADRE (S)) or each of the DNA vaccines administered separately on different locations (opposite sides) of the mouse abdominal wall (CRT/E7+Ii-PADRE (D)). Splenocytes from vaccinated mice were harvested and characterized for the presence of E7-specific CD8 + T cells by intracellular IFN-g staining and flow cytometry analysis. As shown in Figure 1a , a significantly higher number of E7-specific CD8 + T cells were observed in mice vaccinated with DNA encoding CRT/E7+Ii-PADRE (S) compared to mice vaccinated with DNA encoding CRT/E7+Ii-PADRE (D). A graphical representation of the number of E7-specific CD8 + T cells is depicted in Figure 1b . Thus, our data indicate that mice vaccinated with the DNA vaccine encoding CRT/E7 and Ii-PADRE administered together at the same location induces a stronger E7-specific CD8 + T-cell immune response compared to administration of CRT/E7 and Ii-PADRE DNA separately.
We also determined the number of PADRE-specific CD4 + T cells using splenocytes from vaccinated mice stimulated with PADRE peptide using intracellular IFNg staining followed by flow cytometry analysis. A similar number of PADRE-specific CD4 + T cells were observed in mice vaccinated with DNA encoding CRT/E7+Ii-PADRE (S) compared to mice vaccinated with DNA encoding Figure 1 Flow cytometry analysis of E7-specific CD8 + T cells in mice vaccinated with CRT/E7 and Ii-PADRE DNA. C57BL/6 mice (five per group) were vaccinated intradermally via gene gun with the CRT/E7 DNA and Ii-PADRE DNA, either administered together at the same location (CRT/E7+Ii-PADRE (S)) or each of the DNA vaccines administered separately at different locations (on opposites sides) of the mouse abdominal wall (CRT/E7+Ii-PADRE (D)). Mice received DNA vaccination with the same dose and regimen 1 week later. The splenocytes were obtained from vaccinated mice and cultured with E7 peptide (aa 49-57) overnight. The cells were then analyzed for CD8 and intracellular IFNg staining by flow cytometry. Figure 2b . Thus, our data indicate that vaccination with Ii-PADRE DNA is capable of generating PADRE-specific CD4 + T cells with Th1 cytokine profile.
DCs loaded with E7 and PADRE peptide generate a stronger E7-specific CD8 + T-cell immune response compared to DCs loaded with E7 alone in vaccinated mice
The observations from the DNA vaccination via gene gun in mice suggest that DCs expressing both E7 and PADRE may be important for the enhancement in E7-specific CD8 + T-cell responses ( Figure 1 ). To confirm this, we employed a DC line and loaded the DCs with E7 in conjunction with PADRE peptide for in vivo vaccination studies. Furthermore, to determine whether the enhancement of E7-specific CD8 + T-cell immune responses is unique to PADRE, we included DCs pulsed with E7 and OVA peptides for comparison. C57BL/6 mice were vaccinated subcutaneously with DCs pulsed with both E7 and PADRE (DC-PADRE/E7) or DCs pulsed with both E7 and OVA (DC-OVA/E7). In addition, mice vaccinated with DCs pulsed with E7 (DC-E7) were included for comparison. As a negative control, one group of mice was vaccinated with DCs without peptide. Mice were vaccinated with the same dose and regimen 1 week later. Splenocytes from vaccinated mice were harvested 1 week after the last vaccination and characterized for the presence of E7-specific CD8 + T cells by intracellular IFN-g staining and flow cytometry analysis. As shown in Figure 3a , a significantly higher number of E7-specific CD8 + T cells was observed in mice vaccinated with DC-PADRE/E7 compared to mice vaccinated with DC-OVA/E7 or mice vaccinated with DC-E7 (Po0.05). In contrast, only background levels of E7-specific CD8 + T cells were observed in mice vaccinated with DCs alone. A graphical representation of the number of E7-specific IFN-g + CD8 + T cells in each group is depicted in Figure  3b . Thus, our data indicate that vaccination with DCs pulsed with E7 and PADRE induces a stronger E7-specific CD8 + T-cell immune response than DCs pulsed with E7 alone. In addition, the enhancement of E7-specific CD8 + T-cell immune responses appears to be unique to PADRE peptide since vaccination with DCs pulsed with E7 and OVA does not increase the E7-specific CD8 + T-cell immune responses.
Administration of DCs loaded with E7 and DCs loaded with PADRE mixed together at the same location generates stronger E7-specific CD8 + T-cell immune responses compared to DCs loaded with E7 and DCs loaded with PADRE administered at different locations
In our DNA vaccination studies, we observed that intradermal administration of CRT/E7 and Ii-PADRE DNA at the same location generated stronger E7-specific CD8 + T-cell immune responses compared to administration of CRT/E7 and Ii-PADRE DNA separately ( Figure  1 ). These data suggest that DCs expressing PADRE are required to be in the vicinity of DCs expressing E7 to generate the observed enhancement of E7-specific CD8 + T-cell responses. To test this, we employed DCs pulsed with either PADRE or E7 administered at the same location or at different locations and examined their ability to generate E7-specific CD8 + T-cell responses. C57BL/6 mice were injected with DCs loaded with E7 on the right footpad and DCs loaded with PADRE on the left footpad (E7(R)+PADRE(L)). Another group of mice was vaccinated with the DC-based vaccine combining the E7-loaded DCs and the PADRE-loaded DCs administered on each footpad (E7/PADRE (mixed DC). As a negative control, one group of mice was vaccinated with DCs without peptide. Mice were vaccinated with the same dose and regimen 1 week later. Splenocytes from vaccinated mice were harvested 1 week after the last vaccination and characterized for the presence of E7-specific CD8 + T cells by intracellular IFN-g staining and flow cytometry analysis. As shown in Figure 4a , a significantly higher number of E7-specific CD8 + T cells was observed in mice vaccinated with E7/PADRE (mixed DC) compared to mice vaccinated with E7(R)+PADRE(L) (Po0.05). In contrast, only background levels of E7-specific CD8 + T cells were observed in mice vaccinated with the DCs alone. A graphical representation of the number of E7-specific IFN-g + CD8 + T cells is depicted in Figure 4b . Thus, our data indicate that vaccination with a DC-based vaccine combining the E7-loaded DCs and the PADRE-loaded DCs at the same location induces a stronger E7-specific CD8 + T-cell immune response.
We also determined the number of PADRE-specific CD4 + T cells generated by vaccination with the various DC-based vaccines, including
IL-2 enhances antigen-specific CD8 + T-cell immune responses D Kim et al E7/PADRE (mixed DC) and DCs alone. Splenocytes from vaccinated mice were examined for PADRE-specific CD4 + T cells using intracellular IFN-g staining followed by flow cytometry analysis. We observed a comparable number of PADRE-specific IFN-g-secreting CD4
+ T cells in mice vaccinated with E7/PADRE (mixed DC) compared to mice vaccinated with E7(R)+PADRE(L) (Supplementary Figure 2) . In contrast, only background levels of PADRE-specific CD4 + T cells were observed in mice vaccinated with the DCs alone. Thus, our data indicate that the location of vaccination with DCs loaded with E7 and DCs loaded with PADRE does not influence Taken together, our data suggest that PADRE-loaded DCs are required to be in the vicinity of E7-loaded DCs to generate a stronger E7-specific CD8 + T-cell immune response. In comparison, the generation of PADREspecific CD4 + T-cell responses is not influenced by the location of administration of PADRE-loaded DCs and E7-loaded DCs.
In vitro stimulation of the PADRE-specific CD4 + T-cell line with DCs pulsed with PADRE resulted in Th1 phenotype
As mentioned above, CD4 + T helper cells, particularly Th1, are important for the generation of cell-mediated immunity. We generated a PADRE-specific CD4 + T-cell line as described in the Materials and methods. Thus, to determine whether the cytokine profile expressed by the PADRE-specific CD4 + T-cell line stimulated in vitro with DCs loaded with PADRE peptide represents Th1 or Th2 phenotype, the PADRE-specific CD4 + T-cell line was then stimulated in vitro with DCs loaded with PADRE peptide (DC+PADRE) or DCs alone and characterized for the cytokine profile, including IL-2, IFN-g, TNF-a, IL-4 or IL-10 using intracellular cytokine staining followed by flow cytometry analysis. As shown in Figure 5 , the PADREspecific CD4 + T cells stimulated with PADRE-pulsed DCs showed significantly higher numbers of CD4 + T cells secreting IL-2, IFN-g and TNF-a compared to those stimulated with DCs alone. Thus, our data indicate that in vitro stimulation of the PADRE-specific CD4 + T-cell line with PADRE-pulsed DCs skews the cytokine profile of the CD4 + T cells to a Th1 phenotype.
Stimulation of PADRE-specific CD4 + T cells with PADRE-loaded DCs leads to the IL-2-mediated proliferation of E7-specific CD8 + T cells
We observed that stimulation of PADRE-specific CD4 + T cells with PADRE-loaded DCs led to expression of Th1 cytokine profile, including IL-2 ( Figure 5 ). Thus, to determine the role of activated PADRE-specific CD4 + T cells in the proliferation of E7-specific CD8 + T cells, we employed an E7-specific CD8 + T-cell line that expresses luciferase (E7T-LUC). 11 We have previously shown that the luminescence intensity correlates with the number of E7T-LUC cells. 11 We then performed a proliferation assay using E7T-LUC cells incubated with irradiated TC-1 cells into 24-well plates. PADRE-specific CD4 + T cells (PADRE-CD4) and DCs loaded with or without PADRE were added in wells as indicated in the table of Figure 6a . We also included the addition of IL-2 as a positive control. The proliferation of the E7-specific CD8 + T cells was characterized using bioluminescence imaging. As shown in Figure 6a , there was significantly higher luciferase activity in the wells containing both PADREspecific CD4 + T cells and PADRE-loaded DCs compared to the wells containing PADRE-specific CD4 + T cells and DCs alone (Po0.05). Furthermore, the wells containing PADRE-loaded DCs without PADRE-specific CD4 + T cells showed only background levels of luciferase activity (data not shown). A bar graph representing the bioluminescence activity of the E7-specific CD8 + T cells is depicted in Figure 6b . As an alternative to assess the 
IL-
+ T cells, these cells were pulsed with corboxyfluoroscein succinimidyl ester (CFSE) and incubated with PADRE-specific CD4 + T cells together with DCs pulsed with or without PADRE. E7-specific CD8 + T cells alone were included as a negative control and E7-specific CD8 + T cells incubated with IL-2 were included as a positive control. We then characterized the proliferation of the E7-specific CD8 + T cells by flow cytometry analysis in the presence of irradiated TC-1 cells. As shown in Figure 6c , a high proliferation of E7-specific CD8 + T cells (E7-CD8) was observed when incubated with PADREspecific CD4 + T cells (PADRE-CD4) and PADRE-loaded DCs (DC-PADRE) compared to those incubated with PADRE-specific CD4 + T cells and DCs alone as depicted by the CFSE-staining pattern. Furthermore, the proliferation of E7-specific CD8 + T cells incubated with PADREspecific CD4 + T cells and PADRE-loaded DCs was abolished when incubated with an IL-2-blocking antibody (Figure 6d ). Taken together, our data indicate that PADREspecific CD4 + T cells activated by PADRE-loaded DCs secrete IL-2 that can lead to the proliferation of E7-specific CD8 + T cells in vitro.
Discussion
In the current study, we investigated the mechanisms by which PADRE-specific CD4 + T cells enhance the HPV E7-specific CD8 + T-cell immune responses in vaccinated mice. We observed that intradermal administration of CRT/E7 and Ii-PADRE DNA at the same location generated stronger E7-specific CD8 + T-cell immune responses compared to administration of CRT/E7 and Ii-PADRE DNA separately. Furthermore, we observed that vaccination with Ii-PADRE DNA generated PADREspecific CD4 + T cells expressing Th1 phenotype. Our experiments using DC-based vaccines demonstrated that DCs loaded with E7 and PADRE peptide generated a stronger E7-specific CD8 + T-cell immune response compared to DCs loaded with E7 alone in vaccinated mice. In addition, administration of DCs loaded with E7 and DCs loaded with PADRE mixed together at the same location generated stronger E7-specific CD8 + T-cell immune responses compared to DCs loaded with E7 and DCs loaded with PADRE administered at different locations. In vitro stimulation of the PADRE-specific CD4 + T-cell line with DCs pulsed with PADRE was shown to generate PADRE-specific CD4 + T cells expressing Th1 phenotype. Finally, we showed that PADREspecific CD4 + T cells stimulated with PADRE-loaded DCs secreted IL-2 that led to the proliferation of E7-specific CD8 + T cells. Thus, our data suggest that activated PADRE-specific CD4 + T helper cells may be required at the vicinity of the antigen-specific CD8 + T cells where they secrete IL-2, which enhances the antigen-specific CD8 + T-cell immune response. 
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The current study serves to explore the role of PADREspecific CD4 + T cells in the generation of increased number of antigen-specific CD8 + T cells via CD4 + T-cellmediated help mechanisms. Several models have been proposed to illustrate this role of CD4 + T cells in enhancing the antigen-specific CD8 + T-cell immune responses. [12] [13] [14] [15] [16] Among these models, the 'three-cell interaction' model, which proposes that antigen-presenting cells (APCs) deliver co-stimulatory signals to the CD4 + T helper cells, which in turn generate IL-2. This IL-2 production is thought to be necessary for CTL activation. 12, 13, 17, 18 In our study, we show that the PADRE-specific CD4 + T-cell line can be activated by PADRE-loaded DCs to release Th1 type of cytokines including IL-2 ( Figure 5 ). Furthermore, incubation of E7-specific CD8 + T cells with activated PADRE-specific CD4 + T cells stimulated by PADRE-loaded DCs led to the proliferation of E7-specific CD8 + T cells and this proliferation was abolished by incubation with an IL-2-blocking antibody ( Figure 6 ). Thus, although we cannot exclude the possible contributions of the other models, our data are most consistent with the 'three-cell interaction' model illustrating the role of CD4 + T cells in enhancing antigen-specific CD8 + T-cell immune responses.
The Ii-PADRE DNA vaccination strategy to enhance antigen-specific CD8 + T-cell responses appears to be quite specific. We observed in our study that the enhancement of E7-specific CD8 + T-cell immune responses by co-administration of Ii-PADRE DNA is unique to PADRE since vaccination with DNA encoding Ii-OVA (CLIP replaced by OVA MHC class II epitope in the Ii chain) or Ii-E7 (CLIP replaced by E7 MHC class II epitope in the Ii chain) does not increase the E7-specific CD8 + T-cell immune responses (data not shown). Furthermore, in the current study, we showed that only DCs loaded with E7 and PADRE but not DCs loaded with E7 and OVA were able to generate enhanced E7-specific CD8 + T-cell responses (Figure 3) . Such discrepancy may be accounted for by the affinity of the PADRE peptide to MHC class II molecule. PADRE has been shown to be approximately 1000 times more powerful in its capacity to elicit CD4 + T helper cells compared to some natural T-cell epitopes. 19 The innovative strategy to enhance antigen-specific CD8 + T-cell immune responses by co-administration of DNA vaccines with Ii-PADRE DNA may prove to be a highly useful approach that can be widely applied in different antigenic systems. It has been shown that PADRE can be presented by different kinds of MHC class II molecules including different species. Thus, the Ii-PADRE DNA can potentially be used in different individuals with different MHC haplotypes. 19 Furthermore, we have shown that Ii-PADRE DNA can be used in DNA vaccines targeting different antigenic systems such as HPV-16 E6. 10 Thus, Ii-PADRE DNA technology may represent a platform technology to enhance DNA vaccine potency in different individuals with different antigenic systems.
Strategies employing Ii-PADRE DNA can also be potentially used in conjunction with other strategies that modify the properties of DCs to further enhance DNA vaccine potency (for reviews, see Hung and Wu 5 and Tsen et al.
6
). These various strategies work by employing different mechanisms that are not mutually exclusive to each other. Thus, DNA vaccines combining these strategies generate a significant enhancement in DNA vaccine potency. For example, DNA vaccines employing intracellular targeting strategies can be further enhanced by co-administration with Ii-PADRE DNA (D Kim et al., unpublished data). Thus, it is conceivable that such combination strategies may be employed for future clinical translation to generate most potent antigenspecific immune responses.
Materials and methods
Mice C57BL/6 mice (6-8 weeks old) were purchased from the National Cancer Institute, Frederick, MD, USA. All animals were maintained under specific pathogen-free conditions at the Johns Hopkins Hospital (Baltimore, MD, USA). All procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals. + T-cell line was stimulated in vitro with DCs pulsed with or without PADRE peptide. The cells were then analyzed for expression of IL-2, IFN-g, TNF-a, IL-4 and IL-10 by intracellular cytokine staining followed by flow cytometry.
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Cells, antibodies and reagents E7-expressing murine tumor model, TC-1, has been described previously. 20 In brief, HPV-16 E6 and E7 and the ras oncogene were used to transform primary C57BL/6 mouse lung epithelial cells to generate TC-1.
DCs were generated from the DC line 21 provided by Dr Kenneth Rock (University of Massachusetts, Boston, MA, USA). The production and maintenance of E7-specific CD8 + T cells have been described in a previous paper.
22
Firefly luciferase-expressing E7-specific CD8 + T cells IL-2 enhances antigen-specific CD8 + T-cell immune responses D Kim et al (E7T-LUC) were generated using retrovirus-containing luciferase. 11 The retrovirus was produced using a pLucithy1.1 construct expressing both luciferase and thy1.1. The pLuci-thy1.1 was transfected into Phoenix-packaging cell line and the virion-containing supernatant was collected 48 h after transfection. The supernatant was immediately treated using a 0.45-mm cellulose acetate syringe filter (Nalgene, Rochester, NY, USA) and used to infect E7-specific CD8 + T cells in the presence of 8 mg ml À1 polybrene (Sigma, St Louis, MO, USA). E7T-LUC cells were isolated using preparative flow cytometry of stained cells with Thy1.1 antibody using methods similar to our previous study. 23 All cells were maintained in RPMI medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 20 mM HEPES, 50 mM b-mercaptoethanol, 100 IU ml À1 penicillin, 100 mg ml À1 streptomycin and 10% fetal bovine serum (FBS) (Gemini Bio-Products, Woodland, CA, USA). Anti-mouse CD8a mAb (clone 53.6.7), CD4 (clone GK1.5), IL-2, IL-4, IL-10, IFN-g and TNF (BD Pharmingen, San Diego, CA, USA) were used for intracellular cytokine analysis. Phycoerythrin-conjugated Thy1.1 mAb was used to sort the E7T-LUC. CFSE was purchased from Molecular Probes (Carlsbad, CA, USA).
Plasmid DNA constructs and DNA preparation
The generation of pcDNA3-CRT/E7 Ii-PADRE has been described previously. 10, 24 The DNA construct encoding an Ii chain was constructed by real-time PCR amplification using RNA isolated from DCs and primers (5 0 aaagaattcatggatgaccaacgcgacctc3 0 and 5 0 aaaggatcctca cagggtgacttgacccag3 0 ). The reverse transcriptase-PCR product was cloned into the EcoRI/BamHI sites of pcDNA3.1(À) to generate pcDNA3-Ii. The DNA fragment encoding the PADRE epitope and Ii chain 103-279 amino acids was amplified by PCR with a set of primers (5 0 aaaggatcctcacagggtgacttgacccag3 0 , 5 0 ctggaccctgaaggct gccgctatggataacatgctccttgg3 0 and 5 0 gccaagttcgtggctgcctgg accctgaaggctgccgct3 0 ). The overlapping PCR fragments were then used as template to create Ii-PADRE using PCR with a set of primers (5 0 aaagaattcatggatgaccaac gcgacctc3 0 and 5 0 aaaggatcctcacagggtgacttgacccag3 0 ). The DNA fragment encoding Ii-PADRE was further cloned into EcoRI/BamHI of pcDNA3.1(À) vector to generate pcDNA3-Ii-PADRE. The accuracy of these constructs was confirmed by DNA sequencing. DNA was amplified in Escherichia coli DH5a and purified as described previously. 25 
DNA vaccination
DNA-coated gold particles were prepared according to a protocol described previously. 25 DNA-coated gold particles were delivered to the shaved abdominal region of mice using a helium-driven gene gun (Bio-Rad Laboratories Inc., Hercules, CA, USA) with a discharge pressure of 400 p.s.i. C57BL/6 mice were immunized with 2 mg of the plasmid encoding pcDNA3-CRT/E7 mixed with pcDNA3-Ii-PADRE for the vaccination strategy at the same location. The mice received a booster with the same dose and regimen 1 week later. For the vaccination strategy at different locations, mice were immunized intradermally via gene gun with pcDNA3-CRT/E7 (1 mg per mouse, right side of the abdomen) and pcDNA3-Ii-PADRE (1 mg per mouse, left side of the abdomen), and boosted with same regimen at same side 1 week later.
DC immunization
DCs were co-pulsed with HPV-16 E7 (aa 49-57) peptide (RAHYNIVTF, 10 mg ml
À1
) and PADRE peptide (AKF-VAAWTLKAAA, 10 mg ml 
. DCs (100 ml per mouse) were injected into mice via footpad injection. One week later, the mice were boosted once with the same dose and immunization regimen. For comparing the effect of PADRE on the vaccination strategy at different locations vs with mixed DCs, one group of DCs was pulsed with E7 aa 49-57 peptide (RAHYNIVTF, 5 mg ml À1 ), which was injected into the right footpad. The other group of DCs was pulsed with PADRE peptide (AKFVAAWTLKAAA, 5 mg ml À1 ), which was injected into the left footpad. For the vaccination strategy using mixed DCs, each group of pulsed DCs was put together just after washing process before immunization, and then those cells were vaccinated with equal number and volume.
Intracellular cytokine staining and flow cytometry analysis
Splenocytes were harvested from mice 1 week after the last vaccination. Prior to intracellular cytokine staining, 5 Â 10 6 pooled splenocytes from each vaccination group were incubated for 16 h with 1 mg ml À1 HPV-16 E7 H-2D b epitope (RAHYNIVTF), and PADRE peptide (AKFV AAWTLKAAA) or OVA peptide (ISQAVHAAHAEINE AGR) in the presence of GolgiPlug (BD Pharmingen) (1 ml ml
À1
). The stimulated splenocytes were then washed once with FACScan buffer and stained with phycoerythrinconjugated monoclonal rat anti-mouse CD8a or CD4. Cells were subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to the manufacturer's 
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+ T-cell immune responses D Kim et al instructions (BD Pharmingen). Intracellular IFN-g was stained with fluorescein isothiocyanate-conjugated rat anti-mouse IFN-g to identify the immune response and cytokine levels. Fluorescein isothiocyanate-conjugated rat anti-mouse IL-2, IL-4, IL-10 and TNF were used to detect intracellular cytokine levels. Flow cytometry analysis was performed using FACSCalibur with CELLQuest software (BD Biosciences, Mountain View, CA, USA).
Generation of a PADRE-specific CD4 + T-cell line
Six-week-old female C57BL/6 mice were immunized with pcDNA3-Ii-PADRE by gene gun. After prime and booster vaccination at 1-week interval, splenocytes were harvested 1 week after the last vaccination. For initial in vitro stimulation, 5 Â 10 6 splenocytes were pulsed with IL-2 (10 U ml
À1
) and PADRE peptide (1 mg ml À1 ) in RPMI media containing 10% FBS for 6 days. Propagation of the PADRE-specific CD4 + T-cell line was performed in 24-well plates by mixing 1 Â 10 6 splenocytes containing PADRE-specific CD4 + T cells with 1 Â 10 6 irradiated DCs that were pulsed with PADRE peptide, and then cultured in RPMI media containing IL-2 (10 U ml À1 ) for 6 days. This procedure was repeated weekly. Flow cytometry was performed to demonstrate the expression of the CD4 marker.
DCs and PADRE-specific CD4 T cells co-culture assay PADRE-specific CD4 + T cells (1 Â 10 6 per well) were cultured with irradiated DCs or PADRE-pulsed DCs (1 Â 10 5 per well) in 24-well plates for 16 h. Cells were then stained for both surface CD4 and the indicated cytokines, and analyzed by flow cytometry analysis as described above.
In vitro bioluminescence imaging
For in vitro proliferation assay, we used the bioluminescence imaging system. Luciferase-transfected E7-specific T cells (E7T-LUC) (2 Â 10 5 per well) were mixed with irradiated TC-1 cells (2 Â 10 4 per well) in 24-well plates with complete media. Irradiated DCs or PADRE peptidepulsed DCs (1 Â 10 5 per well) and PADRE-specific CD4 + T cells (1 Â 10 5 per well) were added to each well according to the indicated conditions. The plates were incubated at 37 1C 5% CO 2 for 3 days. At day 3, Dluciferin (potassium salt; Xenogen Corp., Alameda, CA, USA) at 150 mg ml À1 in media was added to each well 7-8 min before imaging. Imaging process was conducted on a cryogenically cooled IVIS system (Xenogen Corp.) using Living Image acquisition and analysis software (Xenogen Corp.). Imaging time was 1 min per plate.
CFSE labeling of T cells and IL-2-blocking experiment

E7-specific CD8
+ T cells were labeled at 1 Â 10 7 cells ml À1 with 5 mM CFSE (Molecular Probes) in phosphatebuffered saline (PBS) for 5 min at room temperature followed by incubation with 5% FBS-PBS (5 mM EDTA) for 10 min at 371C. After three washes with 5% FBS-PBS, 1 Â 10 6 ml À1 of the labeled cells in 200 ml of media were mixed at the indicated conditions in a 24-well plate. IL-2 blocking was achieved by anti-IL-2 mAb (10 mg ml À1 ; close JES6-1A12; R&D Systems, Minneapolis, MN, USA). Rat immunoglobulin G2a mAb (10 mg ml
À1
; close 54447; R&D Systems) was used as isotype control. All wells contained 2 Â 10 4 irradiated TC-1 cells. After 4 days of culture, flow cytometry acquisition was carried out as described above.
Statistical analysis
All data expressed as means±s.d. are representative of at least two different experiments. Data for intracellular cytokine staining with flow cytometry analysis and tumor treatment experiments were evaluated by analysis of variance. Comparisons between individual data points were made using Student's t-test. All P-values o0.05 were considered significant.
